Thursday, 15 October 2026European Markets

ATLANTIC SAPPHIRE Stock Bullish Momentum With A 28.03% Jump On Monday

Loading stream...

(VIANEWS) - The Market ended the session with ATLANTIC SAPPHIRE (ASA.OL) jumping 28.03% to kr2.12 on Monday, following the last session's upward trend. Oslo Børs Benchmark Index_GI fell 0.07% to kr1,300.03, after two consecutive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

ATLANTIC SAPPHIRE's last close was kr1.65, 91.89% under its 52-week high of kr20.36.

About ATLANTIC SAPPHIRE

Atlantic Sapphire ASA, together with its subsidiaries, engages in the land-based salmon farming business. It operates through two segments, Fish Farming (Denmark); and Fish Farming (US). The company is involved in the production and sale of salmon. It operates in the United States, Denmark, and internationally. The company was founded in 2010 and is headquartered in Vikebukt, Norway.

Earnings Per Share

As for profitability, ATLANTIC SAPPHIRE has a trailing twelve months EPS of kr-6.44.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -24.26%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ATLANTIC SAPPHIRE's stock is considered to be oversold (<=20).

Yearly Top and Bottom Value

ATLANTIC SAPPHIRE's stock is valued at kr2.12 at 22:30 EST, way below its 52-week low of kr4.50.

More news about ATLANTIC SAPPHIRE (ASA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com